Ganging up on angiotensin II type 1 receptors in vascular remodeling

Hypertension

Volumn 60, Issue 1, 2012, Pages 17-19

  Gaspari, Tracey A ^a   Vinh, Antony ^a   Jones, Emma S ^a   Widdop, Robert E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PROTO ONCOGENE PROTEINS C MAS 1; PROTO-ONCOGENE PROTEINS C-MAS-1;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; NEOINTIMA; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULITIS; ANIMAL; FEMORAL ARTERY; METABOLISM;

ANIMALS; FEMORAL ARTERY; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84865806121     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.193375     Document Type: Note

References (15)

1. Vinh A, Gaspari TA, Jones ES, Widdop RE. Functional cardiovascular effects of angiotensin peptides: focus on atherosclerosis and hypertension. Curr Hyp Reviews. 2009;5:227-236.
2. Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271.
3. Ferrario CM. Ace2: more of ang-(1-7) or less ang II? Curr Opin Nephrol Hyp. 2011;20:1-6.
4. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res. 2005;38:499-507.
5. Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens. 2011;29:2236-2245.
6. Schindler C, Brosnihan KB, Ferrario CM, Bramlage P, Maywald U, Koch R, Oertel R, Kirch W. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol. 2007;47:112-120.
7. Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodeling. Hypertension. 2012;60:137-144.
8. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, Toffoli B, Nguyen-Huu TP, Head GA, Fu Y, Chin-Dusting J, Cooper ME, Tikellis C. Genetic ACE2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res. 2010;107:888-897.
9. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein e-deficient mice. Art Thromb Vasc Biol. 2010;30:1606-1613.
10. Langeveld B, Van Gilst WH, Tio RA, Zijlstra F, Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension. 2005;45:138-141.
11. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, De Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001;104:2716-2721.
12. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-824.
13. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960-966.
14. Bosnyak S, Widdop RE, Denton KM, Jones ES. Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartantreated rats. Int J Hypertens. 2012;2012:192567.
15. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316.